id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-310419-s3qkscw7	Lephart, Paul R.	Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type()	2020-09-03		.txt	text/plain	2049	110	55	title: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type() The COVID-19 pandemic in the United States created a unique situation where multiple molecular SARS-CoV-2 diagnostic assays rapidly received Emergency Use Authorization by the FDA, were validated by laboratories and utilized clinically, all within a period of a few weeks. Within a few weeks, additional SARS-CoV-2 NAAT options emerged that were specifically designed for rapid testing of patients in the point of care setting: the Cepheid Xpert Xpress SARS-CoV-2 (Xpert) assay, which could provide results in 45 minutes, and the Abbott ID NOW COVID-19 (ID NOW) assay, ultimately approved for direct nasal, nasopharyngeal and throat swab testing only, with results in 5-15 minutes. This comparative analysis of SARS-CoV-2 NAATs utilizing the m2000, Simplexa, Xpert and ID NOW assays demonstrated that significant performance deficits were found in the ID NOW assay when tested in a mixed patient population using both NP and nasal specimens.	./cache/cord-310419-s3qkscw7.txt	./txt/cord-310419-s3qkscw7.txt